SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (418)2/3/2003 9:14:26 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 598
 
>> Never previously heard of this drug or Eximias - they are privately held <<

Yes you have. Thymitaq is the old Agouron molecule. It's toxic as heck, and efficacy is modest at best.



To: Biomaven who wrote (418)2/3/2003 11:48:06 AM
From: Czechsinthemail  Respond to of 598
 
I was surprised that Thymatiq could qualify for Orphan Drug status. I would have thought the market for liver cancer was too large.

Does this mean Orphan Drug status would also be available for T67?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News